NCT03539393Available不适用
Fremanezumab (TEV-48125) Compassionate Use Program for Pediatric Patients (6 to 17 Years) With Chronic or Episodic Migraine
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
This is a Managed Access Program (MAP) based on a licensed physician's unsolicited request on a compassionate basis. Specifically, this MAP is for male and female pediatric patients 6 to 17 years with a diagnosis of either episodic or chronic migraine who have successfully completed the Teva sponsored study TV48125-CNS-30084 (SPACE study).
详细描述
Eligibility for managed access of TV-48125 (fremanezumab) is currently only open to patients have successfully completed the TV48125-CNS-30084 study.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 6 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible patients may enter this CUP after successfully completing TV48125-CNS-30084 and all End of Study procedures
- •In the opinion of your physician/investigator are able to continue IMP (fremanezumab) in a safe and compliant way.
排除标准
- •Additional criteria may apply, please contact your physician/investigator for more information.
研究者
相似试验
Available
不适用
A Compassionate Use (CU) Program of OdronextamabRelapsed or Refractory (R/R) Follicular Lymphoma (FL)Diffuse Large B-Cell Lymphoma (DLBCL)B-Cell Non-Hodgkin Lymphoma (NHL)High-Grade B-Cell Lymphoma (HGBCL)NCT05619367Regeneron Pharmaceuticals
Available
不适用
Compassionate Use of Concizumab if You Have HaemophiliaCongenital HaemophiliaNCT04921956Novo Nordisk A/S
No Longer Available
不适用
Compassionate Use Program With Brivaracetam for the Treatment of Patients With EpilepsyEpilepsyNCT03532516UCB Biopharma SRL
已完成
3 期
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's SyndromeCushing's DiseaseCushing's SyndromeNCT01371565Corcept Therapeutics4
Available
不适用
Individual Patient Compassionate Use of FedratinibMyelofibrosisNCT03723148Celgene